Semaglutide or Tirzepatide, including micro-dose programs, cannot be prescribed and should not be purchased by individuals with a BMI under 25, an eating disorder, diabetes, gallbladder disease, history of drug or alcohol abuse, recent bariatric surgery, pancreatitis, medullary thyroid cancer or a family history of it, diabetic retinopathy, multiple endocrine neoplasia type 2, or those who are pregnant, breastfeeding, or planning to become pregnant
Oral supplements present a more convenient option, albeit with slower and subtler results
Doseresponse modeling, meta-analysis, and Bayesian hierarchical models were implemented using validated statistical packages
Data on the Frequency of Diarrhea Several studies and clinical trials have been conducted to assess the safety and effectiveness of tirzepatide
Many patients have reported that after initial weeks of therapy, the incidence of nausea decreases significantly or disappears altogether
If tirzepatide genuinely is not working after adequate trial, switching to a different mechanism may help